SCHEMBL374101

SCHEMBL374101

N=C(N)[N]O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431407 0.70
SCHEMBL2981077 0.70
SCHEMBL5929425 0.70
SCHEMBL722863 0.70
SCHEMBL724052 0.70
SCHEMBL608831 0.67
Guanidine SCHEMBL687217 0.67
SCHEMBL10597703 0.67
Hydroxyguanidine SCHEMBL8216664 0.67
SCHEMBL307358 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110092798-A It is a kind of as the heterocyclic compound and its synthetic method of FGFR inhibitor and application 上海新契博生物科技有限公司 2019-08-06 CN claimed
EP-2418205-B1 Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2014-01-22 EP claimed
US-8552002-B2 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea NOVARTIS AG (CH) 2013-10-08 US claimed
EP-2409969-B1 Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2013-07-24 EP claimed
US-20130012704-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS DING QIANG (CN) 2013-01-10 US claimed
US-20130012476-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-01-10 US claimed
EP-2418205-A1 Pyrimidine urea derivatives as kinase inhibitors Novartis AG (CH) 2012-02-15 EP claimed
EP-2409969-A1 Pyrimidine urea derivatives as kinase inhibitors Novartis AG (CH) 2012-01-25 EP claimed
EP-1761505-B1 PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-17 EP claimed
EP-1799265-B1 STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES WILEX AG (DE) 2010-09-08 EP claimed
US-6689763-B2 STREPTOMYCIN BACTERICIDES FOR TREATING INFECTIONS; CULTURES WYETH HOLDINGS CORPORATION 2004-02-10 US claimed
EP-0811002-B1 BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS SCHERING CORP (US) 2004-01-21 EP claimed
US-20030220468-A1 Modified forms of pharmacologically active agents and uses therefor MEDINOX, INC. 2003-11-27 US claimed
US-20030186942-A1 Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders UNIVERSITY OF KENTUCKY 2003-10-02 US claimed
US-20030104986-A1 Streptomycin bactericides for treating infections; cultures AMERICAN CYANAMID COMPANY (US) 2003-06-05 US claimed
WO-2002085310-A2 ANTIBIOTICS AA-896 WYETH HOLDINGS CORPORATION (US) 2002-10-31 WO claimed
US-20020103205-A1 Muscarinic antagonists LOWE DEREK (US) 2002-08-01 US claimed
US-5883096-A DI-N-SUBSTITUTED PIPERAZINE DERIVATIVES; ALZHEIMER*S DISEASE, COGNITION ACTIVATORS; SYNERGISTIC MIXTURES WITH ACETYLCHOLINESTERASE INHIBITORS SCHERING CORPORATION (US) 1999-03-16 US claimed
EP-0811002-A2 BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS SCHERING CORPORATION (US) 1997-12-10 EP claimed
WO-1996026196-A2 BENZYLPIPERIDINES AND PIPERAZINES AS MUSCARINIC ANTAGONISTS SCHERING CORPORATION (US) 1996-08-29 WO claimed